Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766175 | 0.83 | CA14 (0.39) | CA14CA12CA9CA2CA1 | |
| SCHEMBL1786589 | 0.83 | CA14 (0.39) | CA14CA12CA9CA2CA1 | |
| SCHEMBL7940365 | 0.83 | CA14 (0.39) | CA14CA12CA9CA2CA1 | |
| SCHEMBL1786590 | 0.83 | CA14 (0.39) | CA14CA12CA9CA2CA1 | |
| Hydrochloric Acid SCHEMBL17393224 | 0.81 | CA14 (0.38) | CA14CA12CA9CA2CA1 | |
| Hydrochloric Acid SCHEMBL17393225 | 0.81 | CA14 (0.38) | CA14CA12CA9CA2CA1 | |
| SCHEMBL22648515 | 0.80 | SMN1; SMN2 (0.36) | CA14CA12CA9CA2CA1 | |
| Hydrochloric Acid SCHEMBL8763031 | 0.79 | PMP22 (0.37) | CA14CA12CA9CA2CA1 | |
| SCHEMBL31247919 | 0.78 | CA14 (0.43) | CA14CA12CA9CA2CA1 | |
| SCHEMBL10602752 | 0.78 | NOS1 (0.35) | CA14CA12CA9CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105008367-B | It is used as the pyrrolo-triazine class compound of potassium channel inhibitors | 百时美施贵宝公司 | 2017-08-29 | — | — | CN | disclosed |
| EP-2970296-B1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2970296-B1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2970296-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105008367-A | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL MYERS SQUIBB CO | 2015-10-28 | — | — | CN | disclosed |
| US-9050345-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050345-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050345-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2014143610-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014143610-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-11 | — | — | US | disclosed |
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-11 | — | — | US | disclosed |
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNJ2, KCNA4 | CA14 4610/4885CA12 4777/4885CA9 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.